1
|
Perréard M, Florent R, Divoux J, Grellard JM, Lequesne J, Briand M, Clarisse B, Rousseau N, Lebreton E, Dubois B, Harter V, Lasne-Cardon A, Drouet J, Johnson A, Le Page AL, Bazille C, Jeanne C, Figeac M, Goardon N, Vaur D, Micault E, Humbert M, Thariat J, Babin E, Poulain L, Weiswald LB, Bastit V. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. BMC Cancer 2023; 23:223. [PMID: 36894916 PMCID: PMC9999487 DOI: 10.1186/s12885-023-10692-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 02/28/2023] [Indexed: 03/11/2023] Open
Abstract
BACKGROUND Radiotherapy is one of the cornerstones of the treatment of Head and Neck Squamous Cell Carcinomas (HNSCC). However, radioresistance is associated with a high risk of recurrence. To propose strategies (such as combinations with drugs) that could over intrinsic radioresistance, it is crucial to predict the response to treatment. Patient-Derived Tumor Organoids (PDTO) are in vitro tridimensional microtumors obtained from patient' own cancer samples. They have been shown to serve as reliable surrogates of the tumor response in patients. METHODS The ORGAVADS study is a multicenter observational trial conducted to investigate the feasibility of generating and testing PDTO derived from HNSCC for the evaluation of sensitivity to treatments. PDTO are obtained after dissociation of resected tumors remaining from tissues necessary for the diagnosis. Embedding of tumor cells is then performed in extracellular matrix and culture in medium supplemented with growth factors and inhibitors. Histological and immunohistochemical characterizations are performed to validate the resemblance between PDTO and their original tumor. Response of PDTO to chemotherapy, radiotherapy and innovating combinations are assessed, as well as response to immunotherapy using co-cultures of PDTO with autologous immune cells collected from patient blood samples. Transcriptomic and genetic analyses of PDTO allow validation of the models compared to patients' own tumor and identification of potential predictive biomarkers. DISCUSSION This study is designed to develop PDTO models from HNSCC. It will allow comparing the response of PDTO to treatment and the clinical response of the patients from whom they are derived. Our aim is to study the PDTO ability to predict the clinical response to treatment for each patient in view of a personalized medicine as well as to establish a collection of HNSCC models that will be useful for future innovative strategies evaluation. TRIAL REGISTRATION NCT04261192, registered February 7, 2020, last amendment v4 accepted on June, 2021.
Collapse
Affiliation(s)
- Marion Perréard
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Head and Neck Surgery, Caen University Hospital, Caen, France
| | - Romane Florent
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Normandy University, UNICAEN, SF Normandy Oncology, US PLATON, ORGAPRED core facility, Caen, France
| | - Jordane Divoux
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Normandy University, UNICAEN, SF Normandy Oncology, US PLATON, ORGAPRED core facility, Caen, France
| | - Jean-Michel Grellard
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Clinical Research Department, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Justine Lequesne
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Clinical Research Department, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Mélanie Briand
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, Biological Resource Center 'OvaRessources', Caen, France
| | - Bénédicte Clarisse
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Clinical Research Department, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Nathalie Rousseau
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,IRCBN Institut Régional du cancer Basse Normandie, Biological Resource Center 'Tumorotheque de Caen Basse-Normandie', Caen, France
| | - Esther Lebreton
- Clinical Research Department, Caen University Hospital, Caen, France
| | - Brice Dubois
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, North-West Canceropole Data Center, Caen, France
| | - Valentin Harter
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, North-West Canceropole Data Center, Caen, France
| | - Audrey Lasne-Cardon
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Head and Neck Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, 3 avenue du Général Harris, Caen, 14000, France
| | - Julien Drouet
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Oral and Maxillofacial Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Alisson Johnson
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Medical Oncology Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | | | - Céline Bazille
- Department of Pathology, Caen University Hospital, Caen, France
| | - Corinne Jeanne
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Biopathology, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Martin Figeac
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France
| | - Nicolas Goardon
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Cancer Biology and Genetics, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Dominique Vaur
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Department of Cancer Biology and Genetics, UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Emmanuel Micault
- Department of Head and Neck Surgery, Caen University Hospital, Caen, France
| | - Maxime Humbert
- Department of Head and Neck Surgery, Caen University Hospital, Caen, France
| | - Juliette Thariat
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,LPC Caen ENSICAEN/CNRS UMR6534, Caen, France
| | - Emmanuel Babin
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.,Department of Head and Neck Surgery, Caen University Hospital, Caen, France
| | - Laurent Poulain
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.,UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.,Normandy University, UNICAEN, SF Normandy Oncology, US PLATON, ORGAPRED core facility, Caen, France
| | - Louis-Bastien Weiswald
- Normandy University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA laboratory (Precision medicine for ovarian cancers), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France. .,UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France. .,Normandy University, UNICAEN, SF Normandy Oncology, US PLATON, ORGAPRED core facility, Caen, France.
| | - Vianney Bastit
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France. .,Department of Head and Neck Surgery, UNICANCER, Comprehensive Cancer Center François Baclesse, 3 avenue du Général Harris, Caen, 14000, France.
| |
Collapse
|
2
|
Chebib E, Lechien JR, Chekkoury-Idrissi Y, Circiu MP, Distinguin L, Pouliquen C, Hans S. Limitations of Transoral Robotic Total Laryngectomy. J Voice 2020; 35:681-682. [PMID: 33339704 DOI: 10.1016/j.jvoice.2020.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Revised: 11/30/2020] [Accepted: 12/02/2020] [Indexed: 10/22/2022]
Affiliation(s)
- Emilien Chebib
- Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| | - Jérôme R Lechien
- Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
| | - Younes Chekkoury-Idrissi
- Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| | - Marta P Circiu
- Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| | - Léa Distinguin
- Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| | - Christelle Pouliquen
- Department of Pathology, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| | - Stéphane Hans
- Robotic Study Group of Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| |
Collapse
|